Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir vs Valganciclovir for CMV Prophylaxis in African American Kidney Transplant Recipients
NCT06001320Phase 3Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Sep 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of letermovir in cytomegalovirus infection (CMV) (2 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Incidence of cytomegalovirus viremia or symptomatic disease at 1 year. Started Sep 2023; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06001320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001320.